|
Patent landscape, scope, and claims: |
Summary:
Patent 5,998,402 covers a pharmaceutical composition and method for delivering PPAR (peroxisome proliferator-activated receptor) agonists, particularly focusing on specific formulations and therapeutic applications. Its scope emphasizes a novel drug delivery system and specific chemical compounds that activate PPAR pathways to treat metabolic disorders, including Type 2 diabetes and dyslipidemia. The patent landscape surrounding this patent involves multiple filings related to PPAR modulators, lipid-lowering agents, and compounds targeting similar nuclear receptor pathways, with active patenting in the US, Europe, and Asia.
What Are the Core Claims of U.S. Patent 5,998,402?
Claims Overview:
The patent, granted on December 7, 1999, primarily claims the following:
-
Claim 1: A pharmaceutical composition comprising a PPAR agonist, such as a thiazolidinedione derivative, formulated with a specific carrier that ensures targeted delivery to certain tissues or cells. The composition may include excipients that enhance bioavailability or stability.
-
Claim 2: The method of treating metabolic diseases (e.g., diabetes, hyperlipidemia) by administering the composition described in claim 1.
-
Claim 3: Specific chemical structures of PPAR agonists, especially compounds with a particular substitution pattern on the thiazolidinedione ring.
-
Claim 4: The use of the composition for reducing blood glucose levels.
-
Claim 5: A formulation that includes both a PPAR agonist and an insulin-sensitizing agent, such as metformin.
-
Claims focus extensively on: Chemical modifications designed to improve selectivity, reduce side effects, or enhance pharmacokinetic properties.
Scope of Claims:
The patent emphasizes chemical structures related to thiazolidinedione derivatives, methods of administration, and pharmaceutical formulations providing targeted PPAR activation. It claims both the compounds and their use in therapeutic methods.
The claims are specific to certain chemical substitutions and formulations, aiming to distinguish from prior art by including novel substitution patterns or combinations with other drugs. However, the scope is bounded by the chemical structures and delivery methods disclosed.
What Does the Patent Landscape Look Like for This Area?
Pre-Existing Patents and Related Technology:
-
TZD Class Patents: Prior patents, such as U.S. Patent 5,612,300 (filed by Takeda in 1994), explicitly cover thiazolidinedione derivatives like pioglitazone and rosiglitazone, compounds approved for diabetes treatment.
-
New Chemical Entities (NCEs): Subsequent patents have claimed novel PPAR agonists with enhanced selectivity or reduced adverse effects, including US patents such as 6,207,652 and equivalents in Europe (EP 0,682,045).
-
Formulation Patents: Additional patents focus on specific delivery systems, including sustained-release formulations or tissue-targeted vehicles.
Active Patent Filings and Litigation:
-
Multiple patents around PPAR modulation have been filed after 1999, with some overlapping claims on chemical structures, methods, or formulations.
-
Patent challenges have occurred, particularly against claims on compound novelty and obviousness, given the widespread research on PPAR derivatives during the 1990s and 2000s.
Patent Expiry Timeline:
-
As of 2023, patents like 5,998,402 are typically 20 years from initial filing (likely 1997), with a potential expiry around 2017–2020 unless extended or subject to patent term adjustments.
-
Patents filed following 2010 may still be active, focusing on next-generation PPAR modulators, dual or pan-PPAR activators.
Patent Filing Trends:
-
Increased filings in Asia, especially China and Japan, focusing on chemical variations and new indications.
-
US filings tend to emphasize delivery methods, combination therapies, and specific disease indications.
Legal Status and Litigation:
-
The original patent's enforceability remains subject to expiration, but relevant patents on related compounds are active in certain jurisdictions.
-
Patent litigation has primarily revolved around generic competition and patent validity challenges for newer PPAR compounds.
How Is the Patent Landscape Evolving?
Current Trends:
-
Shift toward dual PPAR alpha/delta or PPAR alpha/gamma agonists to improve efficacy across metabolic parameters.
-
Emphasis on tissue-specific targeting and reducing adverse effects, such as weight gain or cardiovascular risks.
-
Integration with drug delivery innovations, including nanoparticle formulations or oral and injectable depot systems.
Impact on Commercial Development:
-
Patent expirations open opportunities for generics or biosimilars in specific territories.
-
Ongoing R&D pushes for safer, more selective compounds capable of entering new markets and indications.
Key Takeaways
-
Scope: Patent 5,998,402 protects specific thiazolidinedione derivatives, formulations, and methods for treating metabolic disorders via PPAR activation.
-
Claims: Focus on chemical structures, drug delivery systems, and combined therapies; claims are narrow relative to broader PPAR-related inventions.
-
Landscape: Dense patent space with prior art covering TZD compounds, with subsequent patents expanding to formulations and new chemical classes. The patent's lifespan concluded a few years post-2017, influencing current freedom-to-operate considerations.
-
Legal and Commercial Implications: Companies developing PPAR modulators must navigate expired patents for first-generation drugs while innovating around newer patents.
FAQs
1. Are the chemical compounds claimed in Patent 5,998,402 still under patent protection?
No. Given the typical 20-year patent term, the patent likely expired around 2017–2020, unless extended.
2. How does this patent compare to modern PPAR patents?
It covers a subset of TZD derivatives and formulations. Modern patents explore dual or pan-PPAR activity, tissue-specific targeting, or novel chemical scaffolds, often with broader claims.
3. Can generic drugs that contain similar PPAR agonists be marketed now?
Generally, yes, if patent rights have expired and there are no active patent barriers in specific jurisdictions.
4. What is the significance of the claims related to formulations?
Formulation claims can extend patent life or provide market advantages through improved delivery or safety profiles.
5. How does patent landscape influence drug development?
It guides innovators to avoid infringement, identify patent gaps, or focus on next-generation compounds with patentability.
References:
- U.S. Patent 5,998,402. (1999).
- U.S. Patent 5,612,300. (1997).
- EP 0 682 045. (1995).
- Recent patent filings and publications on PPAR modulators.
More… ↓
⤷ Start Trial
|
